The barriers to the treatment included stigma about insomnia, a lack of information about treatment options, the health care provider's lack of time and training, and the consideration of insomnia as a low health care priority. Costs and lack of availability are other factors.

"Cognitive behavioral therapy is not a quick fix," he said. "But there is increasing evidence that it is an effective treatment for primary and comorbid insomnia."

Dr. Zee disclosed she has possible financial conflicts of interests with Boehringer Ingelheim, Neurocrine Biosciences, Pfizer Inc., sanofi-aventis and Takeda Pharmaceuticals. Dr. Benca disclosed that she has possible financial conflicts of interest with Takeda Pharmaceuticals, Sanofi-Aventis, Sepracor, GlaxoSmithKline, and Eli Lilly. Dr. Morin disclosed possible financial conflicts of interests with Eli Lilly, Neurocrine Biosciences and Takeda Pharmaceuticals. Dr. Neubauer disclosed possible financial conflicts of interest with Neurocrine Biosciences, Pfizer, Sanofi-Aventis and Takeda Pharmaceuticals.
Pages: 1  2  3  4